Congenital toxoplasmosis: therapeutic strategies.
Foulon
W
W
Department of Obstetrics, Academisch Ziekenhuis, Vrije Universiteit Brussel, Brussels, Belgium. walter.foulon@az.vub.ac.be
D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D015997:Neonatal Screening; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000175:diagnosis / Q000188:drug therapy*; D011256:Pregnancy Outcome; D011295:Prenatal Care / Q000379:methods; D011322:Primary Prevention / Q000379:methods; D011739:Pyrimethamine / Q000627:therapeutic use; D012107:Research Design / Q000592:standards; D015572:Spiramycin / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D014125:Toxoplasmosis, Congenital / Q000175:diagnosis / Q000188:drug therapy* / Q000635:transmission; D016896:Treatment Outcome
D000981:Antiprotozoal Agents; D013449:Sulfonamides; D015572:Spiramycin; D011739:Pyrimethamine